USFDA classifies drug substance facility of Biocon’s arm as voluntary action indicated

31 Oct 2024 Evaluate

The U.S. Food and Drug Administration (USFDA) has classified Biocon’s subsidiary -- Biocon Biologics’ Drug Substance Facility at Biocon Campus, (Site 1) located in Bengaluru, Karnataka, as Voluntary Action Indicated (VAI).

This relates to the cGMP inspection conducted by the agency between February 20- 28, 2024 and pertains to the supply of rh-Insulin (rhI) Drug Substance to the United States. Biocon Biologics remains committed to global standards of Quality and Compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

372.95 4.15 (1.13%)
02-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1878.00
Dr. Reddys Lab 1373.70
Cipla 1537.55
Lupin 2396.30
Zydus Lifesciences 990.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.